high mobility group box 3 pseudogene 2Genealiases: HMG4L2 · HMGB3L2 · dJ550H1.1
Q-omics provides the consensus-scored HMGB3P2 profile across patient tissues and cancer cell-line models. HMGB3P2 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, HMGB3P2 is differentially expressed in 7, with the highest sampling consensus in HNSC. Additionally, HMGB3P2 RNA expression shows 6,369 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight DLBC, HNSC, and STAD as cancer lineages where HMGB3P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HMGB3P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HMGB3P2 survival associations across molecular data types. HMGB3P2 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HMGB3P2 RNA expression–survival associations across cancer types. High HMGB3P2 expression shows unfavorable associations in DLBC, UVM, TGCT, COAD and THCA, but favorable associations in SKCM. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify DLBC as the clearest survival context for HMGB3P2 RNA expression.
This table summarizes HMGB3P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for HMGB3P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HMGB3P2 shows lower tumor expression in THCA and COAD and higher tumor expression in HNSC, LUSC, ESCA and STAD. The HNSC box plot shows higher HMGB3P2 RNA expression in tumor versus normal tissue (log2 FC = +0.051, t-test p = .040).
This table shows molecular features associated with HMGB3P2 in patient tissues and cancer cell lines. In patient samples, HMGB3P2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
